Gyre Therapeutics (GYRE) Total Non-Current Liabilities (2014 - 2026)

Gyre Therapeutics (GYRE) has 10 years of Total Non-Current Liabilities data on file, last reported at $22.2 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $22.2 million, changed 0.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.2 million (changed 0.38% YoY), and the FY2025 annual result was $22.4 million, up 36.81% from the prior year.
• Total Non-Current Liabilities eased to $22.2 million in Q1 2026 per GYRE's latest filing, from $22.4 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $25.2 million in Q4 2023 and troughed at $1.8 million in Q3 2023.
• A 5-year average of $16.3 million and a median of $19.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 1239.05% in 2024 and fell as far as 35.1% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $12.5 million in 2022, then jumped by 101.26% to $25.2 million in 2023, then slumped by 35.1% to $16.4 million in 2024, then surged by 36.81% to $22.4 million in 2025, then retreated by 1.09% to $22.2 million in 2026.
• Business Quant data shows GYRE's Total Non-Current Liabilities at $22.2 million in Q1 2026, $22.4 million in Q4 2025, and $18.7 million in Q3 2025.